跳转到内容

NNZ-2591

维基百科,自由的百科全书
NNZ-2591
臨床資料
其他名稱Cyclo(L-glycyl-L-2-allylproline)
法律規範狀態
法律規範
  • Investigational
识别信息
  • (8aR)-8a-Prop-2-enyl-3,6,7,8-tetrahydro-2H-pyrrolo[1,2-a]pyrazine-1,4-dione
CAS号847952-38-9  checkY
PubChem CID
化学信息
化学式C10H14N2O2
摩尔质量194.23 g·mol−1
3D模型(JSmol英语JSmol
  • C(C=C)[C@@]12N(C(=O)CNC1=O)CCC2

NNZ-2591是一种有机化合物,化学式为C10H14N2O2,它是环(甘氨酸-脯氨酸)二肽英语cyclic glycine-proline的类似物,作为治疗安格曼症候群Phelan-McDermid综合症英语Phelan-McDermid syndromePitt Hopkins综合症英语Pitt Hopkins syndrome[1][2]普瑞德威利症候群[3]的药物而开发。

参考文献

  1. ^ Markati, Theodora; Duis, Jessica; Servais, Laurent. Therapies in preclinical and clinical development for Angelman syndrome. Expert Opinion on Investigational Drugs. 3 July 2021, 30 (7): 709–720. doi:10.1080/13543784.2021.1939674可免费查阅. 
  2. ^ Heussler, Helen S. Emerging Therapies and challenges for individuals with Angelman syndrome. Current Opinion in Psychiatry. March 2021, 34 (2): 123 [2023-12-18]. ISSN 0951-7367. doi:10.1097/YCO.0000000000000674. (原始内容存档于2023-12-18). 
  3. ^ An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) (PWS-001) NCT05879614. clinicaltrials.gov. [6 December 2023]. (原始内容存档于2023-12-18).